Dr. Reddy's shares rise over 1% on strategic collaboration with Alvotech for Keytruda Biosimilar
Shares of Dr. Reddy's Laboratories rose 1.4% to touch the day's high of Rs 1,307.65 on the BSE on Friday, June 6, after the company announced a
strategic collaboration
with
Alvotech
, a global biotech firm, to co-develop and commercialize a biosimilar candidate to Keytruda (
pembrolizumab
) for global markets.
'Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines, and Dr. Reddy's Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as 'Dr. Reddy's'), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets,' Dr. Reddy's said in an exchange filing.
Keytruda, a leading immunotherapy drug used in the treatment of various cancers, generated $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars market.
This partnership represents a significant opportunity for Dr. Reddy's to enter the high-value biosimilar segment for oncology drugs, a category that continues to witness growing demand and heightened competitive activity.
Under the agreement, both parties will jointly develop and manufacture the biosimilar, sharing costs and responsibilities. Importantly, each company will retain the right to commercialize the product globally, subject to certain exceptions.
The deal is expected to accelerate development timelines and expand the global market reach of the biosimilar.
Róbert Wessman, Chairman and CEO of Alvotech, emphasized that the agreement will help deliver cost-effective, critical biologic medicines to patients worldwide by combining Dr. Reddy's commercial strength with Alvotech's R&D and manufacturing expertise.
With this collaboration, Dr. Reddy's further strengthens its pipeline in the biosimilars segment.
'We are pleased to collaborate with Alvotech on the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high-quality, affordable treatment options for patients across the world. Oncology has been a key focus area for us, and this collaboration will enhance our capabilities in this domain, as pembrolizumab represents one of the most critical therapies in immuno-oncology,' said Erez Israeli, CEO of Dr. Reddy's.
Dr. Reddy's Laboratories shares ended Thursday's session higher by 3% at Rs 1,289.90 on BSE.
Also read:
Positive Breakout: These 5 stocks cross above their 200 DMAs
(
Disclaimer
: Recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
12 minutes ago
- Indian Express
Center to develop nine roads leading to Nashik ahead of Kumbh mela
Maharashtra Chief Minister Devendra Fadnavis on Sunday said that all roads connecting Nashik will be developed and upgraded in view of the Simhastha Kumbh Mela in Nashik. A total of nine roads will be developed by the central government ahead of the religious meet in 2027 and as per the preliminary estimate, the work is likely to cost a further Rs 4000 crore. A high-level meeting regarding the highway connecting Nashik was held on Sunday in the presence of Union Road Development Minister Nitin Gadkari at Nagpur. Gadkari extended in-principle approval to the construction of necessary roads and facilities required for the upcoming Kumbh Mela to be held in Nashik as a huge crowd of devotees is expected to arrive, leading to a strain on the traffic system. It was decided that a Detailed Project Report (DPR) will be prepared soon and funds will be made available for this. The routes to be developed include, Ghoti – Pahine – Trimbakeshwar – Jawhar Phata; Dwarka Circle – Sinnar IC 21 (Samruddhi Expressway) Nandur Shingote – Kolhar; Nashik to Kasara; Savli Vihir (IC 20 Samruddhi Expressway) Shirdi – Shani Shingnapur Phata (Rahuri Khurd); Nashik to Dhule; Trimbakeshwar – Jawhar – Manor; Shadow Well – Manmad – Malegaon; Ghoti – Sinnar – Vavi – Shirdi; Shani Shingnapur Phata (Rahuri Khurd) – Ahilyanagar (Kharwandi Phata).The meeting approved the Nashik Ring Road. Along with this, it was decided to make the Nashik to Trimbak road six-lane. 'The cost will be calculated post preparation of the DPR. But the central government has assured all possible financial help as well,' said an official from the Maharashtra Public Works Department (PWD). He added, the estimated Rs 4000 crore is for the construction of roads and additional money will be required for the Nashik ring road project. 'Keeping in view the increasing interest of devotees towards Kumbh Mela and the expected crowd, I had requested Prime Minister Narendra Modi to provide assistance at the central government level for its successful planning and enabling infrastructure road development. As a result this meeting was held today,' said Fadnavis. There are eight important routes to Nashik from Mumbai, Gujarat, Palghar, Pune, Ahilyanagar, Sambhajinagar, Dhule. All these routes and the internal roads in Nashik city and the district also connect to the national highway. The meeting considered the development of all those roads. CM Fadnavis said that the expanded road network will provide more safe facilities to the devotees as it will handle the huge traffic expected during the Kumbh Mela.
New Indian Express
12 minutes ago
- New Indian Express
‘We plan to add 1,700 beds by FY27; 57% beds likely in tier 2/3 cities'
Kochi- and Dubai-based Aster DM Healthcare, founded by Dr Azad Moopen in 1987 with a single clinic in Dubai, expects to complete the takeover of the Blackstone and TPG-backed Quality Care Hospital by the fourth quarter of this fiscal. The takeover will result in the third largest hospital chain Aster Quality Care, after Apollo and Fortis, with 38 hospitals across four brands -- Aster DM, Care Hospitals, KIMS Health and Evercare -- offering over 10,150 beds spread across 27 locations. Aster Quality Care is now jointly controlled by the Moopen family holding 24% and Blackstone owning 30.7%. In an interaction with Benn Kochuveedan of TNIE, Dr Azad Moopen shares his plans and expectations from the largest deal that his group has done. Excerpts: When do you see the merger of Quality Care Hospital getting completed? What are the targets in terms of revenue, profit expansion etc? The merger brings together four leading healthcare brands — Aster DM, Care Hospitals, KIMS Health, and Evercare — forming one of the largest hospital chains with 38 hospitals and over 10,150 beds across 27 cities. Financially, the merger strengthens the balance sheet and cash flow, enabling accelerated expansion plans. We aim to increase bed capacity to around 13,300 beds by FY27, further expanding our reach into tier 2 and 3 cities, providing a platform for sustained growth in the future. The merger is expected to be concluded by Q4FY26, with benefits expected to start flowing in from early FY27. What are the synergies you see from the merger? The merger unlocks significant synergies that will drive growth, operational efficiencies, and enhanced patient care across the combined network. Integrating our extensive hospital portfolios will allow the new entity to benefit from economies of scale by negotiating better terms with suppliers, reducing costs, and streamlining inventory management that will lower operational expenses and improve margins. What is the capex plan for fiscal 2026, especially in light of the merger-driven expansion? How many more hospitals and beds to come up this fiscal? We plan to add 1,700 beds by FY27, taking the total bed tally in India to over 6,800 through the organic route and will further look for expansion through the inorganic route. Our overall capital allocation for expansion across the domestic market is Rs 1,400 crore, of which we have already spent around Rs 350-400 crore. You have announced a Rs 850-crore investment in Kerala. What is the strategic thinking behind focusing so much on Kerala, which is often seen as a relatively mature market? Kerala is now poised for a significant transformation with a planned investment of Rs 850 crore over the next three years. This expansion will be anchored by two major greenfield projects: Aster Capital Trivandrum, a 454-bed tertiary care facility, and Aster MIMS Kasaragod, a 264-bed multispecialty hospital. In addition, our flagship hospital, Aster Medcity in Kochi, is undergoing a substantial upgrade. By FY27, our total bed capacity in Kerala is expected to reach 3,453, marking a milestone in our journey of delivering quality healthcare and driving sustainable growth. Affordable healthcare remains a chimera for the average citizen. What is Aster doing differently on this front? To balance affordability and sustainability, we centralise complex procedures in larger hospitals, while smaller units focus on primary/secondary care. By FY27, as much as 57% of our planned bed additions will be in tier 2/3 cities, reinforcing our commitment to these regions. Technology is key to bridging gaps, with telemedicine set to grow at 20.7% annually till FY30, reaching $15.1 billion. Our digital health arm is expanding tele-ICU, teleradiology, AI-driven diagnostics, IoT monitoring, and EMR platforms to enhance accessibility, affordability, and quality care nationwide. What are the digital initiatives of the group? Some of our technology-driven, patient-friendly initiatives include the introduction of the Aster Health app that offers appointment bookings, e-pharmacy, and access to digital health records. We have come up with AI-powered diagnostic solutions, including the Carpal Tunnel Syndrome detection tool in collaboration with the Indian Institute of Science. We are also expanding the home healthcare services under Aster@Home, providing in-home consultations, diagnostics, and physiotherapy, catering to India's growing elderly and chronic care populations.
Time of India
14 minutes ago
- Time of India
Airline asked to pay 25K compensation to passenger
Mumbai: A consumer commission here has held that a senior citizen suffered "monetarily and mentally" after SpiceJet issued incorrect tickets while rerouting his journey in 2020, and directed the airline to pay a compensation of Rs 25,000 to the passenger. The District Consumer Disputes Redressal Commission, Mumbai (Suburban), in the order passed on June 17, held the budget carrier guilty of "deficient service and negligent behaviour" for the error which caused "mental harassment" to the passenger. In view of the urgent need of the passenger (age not specified in the order), the airline had made an alternate booking- where the wrong ticket was issued- after his initial flight was cancelled due to bad weather. The commission acknowledged that the flight cancellation was beyond the control of the airline, and the Air Traffic Control (ATC) had taken the decision in view of the passengers' safety. It noted the airline had taken all the necessary efforts to provide an alternate ticket to the complainant, However, the said ticket was incorrect and thereby the complainant suffered "monetarily and mentally", it said. The commission further stated the complainant also "acted negligently". "Had the complainant checked the ticket when it was issued, the mistake could have been rectified on the spot and the complainant could have saved himself from further hardship," it said. The complainant, a senior citizen residing in Ghatkopar area here, booked Spicejet tickets from Mumbai to Darbhanga for Dec 5, 2020, and a return journey two days later. While the Mumbai to Darbhanga leg of the journey was completed, the return flight was cancelled due to bad weather. PtI
